In ALK- ALCL, oncogenic mutations in JAK1 and/or STAT3 (Figure 2), which contribute to the consistent activation of the STAT3 signaling pathway, has been identified in nearly 20% of cases. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.